Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Go back to Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting| (NASDAQ: STRO) | Delayed: 27.02 -0.82 (2.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.84 | 52 Week High | $ | |||
| Open | $28.14 | 52 Week Low | $ | |||
| Day High | $28.14 | P/E | N/A | |||
| Day Low | $26.80 | EPS | $ | |||
| Volume | 25,522 | |||||
